Results 1 to 10 of about 166,832 (321)

Warfarin brands [PDF]

Australian Prescriber, 2015
Linda Graudins, Fiona Chen, Ingrid Hopper, Philip A Tideman, Rosy Tirimacco, Andrew St John, Gregory W Roberts   +6 more
openaire   +2 more sources

Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: A population-based study from the United Kingdom [PDF]

, 2022
Antonio González Pérez, Yanina Balabanova, María Eugenia Sáez, Gunnar Brobert, Luis A. Garcı́a Rodrı́guez   +4 more
openalex   +1 more source

Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. [PDF]

, 2019
Adverse drug reactions (ADRs) contribute to hospitalization but data on its economic burden is scant. Pre-emptive pharmacogenetic (PGx) testing can potentially reduce ADRs and its associated costs.
Brunham, Liam R, Chan, Alexandre, Chan, Sze Ling, Ng, Hong Yen, Sung, Cynthia, Wee, Hwee-Lin, Winther, Michael D   +6 more
core   +1 more source

ANALYSIS OF STRUCTURAL FEATURES OF THE KETO-KETAL ISOMERS OF WARFARIN BY SPECTRAL METHODS

Разработка и регистрация лекарственных средств, 2019
As a result of the studies was shown that the relative ratios of isomers by integration in DMSO-d6: (S, R)-warfarin – (S, S)-warfarin – open chain warfarin are 70%: 28%: 2%; in СDCl3 are 45%: 40%: 15%.
A. Z. Abyshev, K. B. Nguyen, L. N. Zinchuk   +2 more
doaj  

Piperine Alters the Pharmacokinetics and Anticoagulation of Warfarin in Rats

Journal of Experimental Pharmacology, 2020
Aref Zayed,1 Wahby M Babaresh,1 Ruba S Darweesh,2 Tamam El-Elimat,1 Sahar S Hawamdeh1 1Department of Medicinal Chemistry and Pharmacognosy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan; 2Department of ...
Zayed A, Babaresh WM, Darweesh RS, El-Elimat T, Hawamdeh SS   +4 more
doaj  

Comparison of the TaqMan and LightCycler systems in pharmacogenetic testing: evaluation of the CYP2C9*2/*3 polymorphisms. [PDF]

, 2006
Background: Pharmacogenetic testing for drugmetabolizing enzymes is not yet widely used in clinical practice. Methods: In an attempt to facilitate the application of this procedure, we have compared two real-time PCRbased methods, the TaqMan_ and the ...
C. ESPOSITO, M. TORIELLO, MAZZACCARA, CRISTINA, P. MECCARIELLO, R. DI FIORE, SACCHETTI, LUCIA   +5 more
core   +1 more source

Ascorbic acid-induced warfarin resistance after breast cancer surgery: a case report and literature review

Frontiers in Pharmacology
Warfarin is an anticoagulant that requires INR-based dosage adjustment. Ascorbic acid may impair warfarin effectiveness according to limited literature.
Pingfa Gao, Yang Shen, Ping Wu, Wenjie Lv, Wenjie Lv   +4 more
doaj   +1 more source

Adapting clinical guidelines to take account of multimorbidity [PDF]

, 2012
Most people with a chronic condition have multimorbidity, but clinical guidelines almost entirely focus on single conditions. It will never be possible to have good evidence for every possible combination of conditions, but guidelines could be made more ...
Alderson, P., Guthrie, B., McMurdo, M.E.T., Mercer, S.W., Payne, K.   +4 more
core   +1 more source

VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People [PDF]

, 2019
Lindsay M. Henderson, Renee Robinson, Lily Ray, Burhan Khan, Tianran Li, Denise A. Dillard, Brian D. Schilling, Mike Mosley, Patricia L. Janssen, Alison E. Fohner, Allan E. Rettie, Kenneth E. Thummel, Timothy A. Thornton, David L. Veenstra   +13 more
openalex   +1 more source

Number needed to treat for net clinical benefit of oral anticoagulants in Asian patients with atrial fibrillation

Journal of Arrhythmia
Background Oral anticoagulants (OAC) can reduce ischemic stroke/systemic embolism (SSE) in patients with non‐valvular atrial fibrillation (AF) while increasing the risk of major bleeding. We aimed to analyze the number needed to treat for the net benefit
Rungroj Krittayaphong, Satchana Pumprueg, Ahthit Yindeengam, Gregory Y. H. Lip   +3 more
doaj   +1 more source